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after randomization for patients not actively bleeding. 
Patients whose bleeding after treatment was estimated 
to exceed 5 units in 24 hr were counted as treatment 
failures. All of these patients who failed treatment were 
removed from the protocol and then treated with either 
ES, THS or both. Despite the break in protocol, the 
results for the second major outcome of the study (sur- 
vival) were attributed to the originally assigned treat- 
ment groups. 
The major findings reported by this study are (i) that 
the frequency of rebleeding 15 months after randomiza- 
tion (but not 27 months afterward) is significantly re- 
duced by combined therapy with propranolol plus ES 
compared with propranolol alone, and (ii) that survival 
is significantly improved at  2 years after randomization 
(but not earlier) by combined therapy with propranolol 
plus ES, compared with propranolol alone. 
The first question to ask before accepting these find- 
ings is whether there are other plausible interpretations 
of the results. In this regard, problems did occur in the 
proficiency with which the treatments were adminis- 
tered. Were the assigned treatments received by the 
subjects? Did they comply with therapy? Were additional 
treatments including abstinence equally applied in the 
treatment groups? 
With respect to the first issue, all 31 subjects in the 
ES plus propranolol group received at least one session 
of sclerotherapy. Although only 29 of the intended 35 
subjects in the THS group received sclerosis, the inves- 
tigators were able to show that this did not influence the 
results of the study. In the propranolol group, however, 
eight of the 31 subjects never did receive the drug. Of the 
97 subjects, 25 had not become stable enough to receive 
the drug, and eight did not receive it because they were 
intolerant or had a contraindication. Thus, 34% of sub- 
jects in the study did not receive the drug. In addition, 
for those subjects who did receive propranolol, compli- 
ance was assessed only for the period until the first 
episode of rebleeding, and the data so collected revealed 
variable compliance. Because it appears that so few sub- 
jects received propranolol alone, what was in essence 
compared in the study is supportive therapy vs. ES VS. 
THS. Regarding the second issue of alcohol abstinence, 
there is no documentation provided in the report to 
answer this question. The possibility exists that those in 
the propranolol plus ES group, who had a lower fre- 
quency of major rebleeding, did better because there the 
number of abstainers was greater and hence the rate of 
progression of the underlying liver disease was lower. 
The second question to ask is how should the results 
for death be interpreted, when there were so many mod- 
ifications of the assigned therapy once the first major 
outcome (major rebleeding) had been reached. What was 
really being compared in the analysis for this outcome is 
whether a policy of treatment with propranolol alone is 
better than either a policy of treatment with propranolol 
plus ES or a policy of propranolol plus THS. Unfortu- 
nately, the efficacies of the three treatments were not 
compared themselves, so that the question of the effect 
of the three treatments on survival remains unclear. 
In summary, the results of this study, which essentially 
compared supportive medical therapy vs. ES vs. THS in 
alcoholic men with severe liver disease, concur with the 
results of previous studies in demonstrating that ES is 
better than supportive medical therapy alone in decreas- 
ing the frequency of rebleeding. Furthermore, the bene- 
fits of ES occur in the first 15 months after the index 
bleed, but are not sustained. Based on this study, it 
remains unclear whether propranolol plus ES is better 
than propranolol alone in preventing rebleeding and it 
remains unclear whether survival is improved by adding 
ES to propranolol in patients with EVB. 
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THE DIFFERENTIATION OF CHOLESTEROL 
AND PIGMENT GALLSTONES 
van Erpecum KJ, van Berge Henegouwen GP, Stoelwin- 
der B, Stolk MFJ, Eggink WF, Govaert WHA. Cholesterol 
and pigment gallstone disease: comparison of the relia- 
bility of three bile tests for differentiation between the 
two stone types. Scand J Gastroenterol 1988; 23:948- 
954. 
ABSTRACT 
Gallbladder biles and stones were obtained at 
116 cholecystectomies for symptomatic gallstone 
disease. All 33 patients younger than 50 years had 
cholesterol stones, whereas 40% of the older pa- 
tients had pigment stones. We compared the reli- 
ability of three different bile tests for the differ- 
entiation between cholesterol and pigment stone 
patients. Whereas both the presence of cholesterol 
monohydrate crystals in fresh gallbladder bile and 
a nucleation time 520 days in ultrafiltered gall- 
bladder bile had a specificity of 100% for choles- 
terol gallstone disease, biliary supersaturation 
with cholesterol (cholesterol saturation index 
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>1.0) had a low specificity. The sensitivity of nu- 
cleation time 520 days for cholesterol gallstone 
disease was 78% in concentrated gallbladder biles 
(biliary total lipid concentration 26 g/dl) but only 
21% in dilute biles (biliary total lipid concentra- 
tion c5 g/dl). In contrast, examination for the 
presence of cholesterol crystals in fresh bile was 
reasonably sensitive both in concentrated and di- 
lute gallbladder biles (sensitivity, 84% and 72%, 
respectively). In addition, duodenal bile obtained 
from 16 patients (10 cholesterol, 6 pigment) before 
cholecystectomy showed cholesterol crystals in 7 
of the cholesterol but in none of the pigment stone 
patients. We conclude that examination of fresh 
bile for cholesterol crystals is a specific and rea- 
sonably sensitive test for cholesterol gallstone 
disease. 
COMMENTS 
Gallbladder stones are traditionally classified as pig- 
ment or cholesterol stones. Pigment stones are a mixture 
of insoluble calcium salts of bilirubinate, carbonate, 
phosphate and long-chain fatty acids, arrayed on a gly- 
coprotein matrix. Pigment stones probably form only if 
bile is supersaturated with calcium bilirubinate, often 
accompanied by supersaturation with calcium carbonate. 
The development of cholesterol gallstones involves a 
triple defect with supersaturation and abnormal rapid 
nucleation of cholesterol as well as altered gallbladder 
motor function (1-3). In 100 cholecystectomized Ameri- 
can patients, Trotman et al. (4) found 23 with pigment 
and 77 with cholesterol cholecystolithiasis. A similar 
distribution has been reported from several other West- 
ern countries and in the present report of van Erpecum 
et al. There is an increasing need to discriminate pigment 
stone carriers from cholesterol stone carriers, since the 
latter patients may be candidates for dissolution therapy 
and/or extracorporeal shock wave lithotripsy (5,6). Due 
to the different mechanisms of stone development in 
patients with pigment and patients with cholesterol 
stones, there have been many attempts to differentiate 
these by analysis of the surrounding bile. 
All of these studies have been hampered by the fact 
that the physicochemical properties of gallbladder bile 
obtained at cholecystectomy may not necessarily reflect 
the same properties of gallbladder bile at  the time of 
gallstone formation. Despite this difficulty, three bile 
tests have been proposed to be useful predictors of cho- 
lesterol stones. 
In an extension of prior investigations, Carey and 
Small (1) determined the cholesterol saturation in bile 
regarding the individual total lipid concentration. All 
patients with cholesterol stones showed supersaturated 
biles, but so did about 50% of the patients with pigment 
stones. However, in the same study, cholesterol mono- 
hydrate crystals were found in the majority of gallbladder 
(83%) and hepatic (58%) bile from cholesterol gallstone 
patients but were not observed in pigment stone patients 
or controls. Although it seemed possible that cholesterol 
crystals, detectable by light microscopy in the gallbladder 
bile of patients with gallstones, are shed from the surface 
of the stone and do not represent de nouo nucleation, 
Holan et al. (2) have indicated that the rate of crystal 
formation and growth is much faster in bile samples from 
cholesterol gallstone patients after removal of crystals 
by ultracentrifugation, in comparison to bile samples 
without crystals from patients with pigment stones. 
van Erpecum et al. have compared the reliability of 
these three bile tests for the differentiation between 
patients with cholesterol or pigment gallstones. They 
found that the microscopical identification of cholesterol 
crystals in bile is a highly specific and a rather sensitive 
method for the diagnosis of cholesterol cholecystoli- 
thiasis in concentrated as well as dilute gallbladder bile. 
This is in agreement with several other reports (1). The 
sensitivity of microscopical detection of cholesterol crys- 
tals for cholesterol gallstone disease was slightly lower 
when duodenal bile from cerulein-stimulated gallblad- 
ders was analyzed. In contrast, the results of the so- 
called cholesterol nucleation time were less useful for the 
differentiation of patients with pigment from patients 
with cholesterol gallstones. Although, a nucleation time 
<20 days in ultrafiltered gallbladder bile had a specificity 
of 100% and a sensitivity of 78% for cholesterol gallstone 
disease in concentrated gallbladder biles, sensitivity de- 
creased to 21% in dilute biles. 
There is a discrepancy between the presence of choles- 
terol crystals in the dilute bile of 72% of the patients 
with cholesterol stones and the normal nucleation time 
of cholesterol >21 days found in most of these patients. 
Methodological problems may be one explanation for 
this difference. In variance with prior studies (2), van 
Erpecum et al. performed ultrafiltration instead of ultra- 
centrifugation to remove crystals prior to the nucleation 
assay. For ultrafiltration, 0.22-pm Millex filters were 
used, which may retain not only crystals or larger cellular 
debris but, additionally, cholesterol-phospholipid vesi- 
cles, particularly if these are fused and aggregated to 
larger complexes. Since aggregated vesicles play a key 
role in the formation of cholesterol crystals (7, 8), re- 
moval of part of those vesicles by ultrafiltration could 
prolong cholesterol nucleation in a subsequent assay. 
This effect may be less evident in concentrated bile. 
However, in dilute bile and with decreasing concentra- 
tions of bile acids, the vesicular fraction in bile increases, 
and larger aggregates are more likely to occur. It is 
therefore conceivable that the results obtained in the 
cholesterol nucleation studies of van Erpecum may be 
affected by the use of ultrafiltration. It would be inter- 
esting to compare van Erpecum’s results to data obtained 
with the conventional nucleation assay as originally de- 
scribed by Holan et al. (2). 
Finally, van Erpecum et al. have proven the reliability 
of the cholesterol saturation index in the differentiation 
of cholesterol and pigment stones. Their results confirm 
many prior investigations (1) that an abnormal choles- 
terol saturation index (>1.0) is a fairly sensitive but 
nonspecific parameter for cholesterol gallstone disease. 
Taken together, van Erpecum’s study shows that the 
microscopical detection of cholesterol crystals in bile is 
a rather sensitive and highly specific method for the 
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diagnosis of cholesterol gallstones. However, a negative 
test result does not exclude the presence of cholesterol 
gallstones, especially if duodenal bile is used. 
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APLASTIC ANEMIA AFTER LIVER 
TRANSPLANTATION FOR FULMINANT 
VIRAL HEPATITIS: BLACK BOX OR BAG 
OF WORMS? 
Tzakis AG, Arditi M, Whitington PF, Yanaga K, Esquivel 
C, Andrews WA, Makowka L, Malatak J, Freese DK, 
Stock PG, Ascher NL, Johnson FL, Broelsch CE, Starzl 
TE. Aplastic anemia complicating orthotopic liver trans- 
plantation for non-A, non-B hepatitis. N Engl J Med 
1988; 319~393-396. 
ABSTRACT 
Aplastic anemia developed in 9 of 32 patients 
(28 percent) undergoing orthotopic liver trans- 
plantation for acute non-A, non-B hepatitis, at one 
to seven weeks after the procedure. No patient 
previously had evidence of hematologic dysfunc- 
tion or conditions known to be associated with 
aplastic anemia. No other cases of aplastic anemia 
were identified among 1463 patients undergoing 
liver transplantation for all other indications at 
the four centers participating in the study (chi- 
square = 415, P c 0.001; 95 percent confidence 
interval for the incidence of aplastic anemia after 
transplantation for non- A, non-B hepatitis, 13 to 
44 percent, vs. 0.00 to 0.13 percent for all other 
indications). 
The operative and postoperative treatment of 
these patients was not otherwise different, indi- 
cating that the aplastic anemia was a complication 
of the hepatitis, not of the transplantation proce- 
dure. Four of the nine patients died of complica- 
tions due to infections. Three of the surviving 
patients have been followed for less than six 
months, one for one year, and one for two years. 
The two patients followed the longest have re- 
covered marrow function to an appreciable de- 
gree, and two of the others have evidence of early 
recovery. 
We concluded that patients undergoing ortho- 
topic liver transplantation for non-A, non-B hep- 
atitis are at a high risk for the development of 
aplastic anemia. 
COMMENTS 
The discovery of a cohort of patients who develop 
aplastic anemia after liver transplantation only accen- 
tuates an already described phenomenon. Every form of 
viral hepatitis is associated with both transient and 
severe bone marrow depression. In the United States, 
approximately 5 to 7% of all patients with aplastic ane- 
mia have had an antecedent episode of clinical hepatitis. 
Up to 40% of patients being referred to bone marrow 
transplant centers for aplastic anemia have elevated 
aminotransferases. The true incidence of hepatitis and 
viral-associated aplastic anemia is not clear, since most 
patients do not have an exhaustive evaluation for the 
dozen or so viruses that have been implicated in causing 
severe bone marrow depression. Cyclosporin and steroid 
therapy in and of themselves do not appear to induce 
aplastic anemia. Most of the 1,495 patients who received 
liver transplants presumably were treated with cyclo- 
sporin and corticosteroids, but only nine patients devel- 
oped aplastic anemia. Furthermore, aplastic anemia in 
renal transplant recipients is extraordinarily rare. 
Hepatitis A, B and non-A, non-B can directly depress 
the in vitro differentiation and proliferation of normal 
human bone marrow (1-4). Hepatitis A and B virus 
depress bone marrow only if there is at least one virion 
per mononuclear cell. This effect can be prevented by 
antibodies. Bone marrow is routinely infected with hep- 
atitis B virus during acute and chronic hepatitis B. By 
in situ hybridization and Southern blot analysis, we and 
others have found hepatitis B virus DNA in human bone 
marrow and circulating mononuclear cells, including T 
cells, B cells, and monocytes (5, 6). The percentage of 
nucleated bone marrow cells that contain viral DNA, 
HBsAg or HBcAg is 3 to 5%. Despite these in vitro 
findings, we cannot entirely explain bone marrow depres- 
sion as a direct effect of the virus on stem cell function. 
Since transient aplasia is usually concurrent with acute 
hepatitis, bone marrow depression is likely a consequence 
of immunological attack on infected bone marrow stem 
cells. 
Hepatitis and other types of viral-associated aplastic 
anemia may be nothing more than manifestations of 
severe immunological injury of bone marrow that results 
in destruction of either all progenitor cells or the mi- 
croenvironment necessary to allow continued growth of 
bone marrow. Evidence for this hypothesis is exemplified 
with Epstein-Barr virus (EBVbassociated aplastic ane- 
mia and with cytomegalovirus (CMV)-infected bone 
